Moderna, Inc.
22.6.2022 14:03:42 CEST | ACCESS Newswire | Press release
mRNA-1273.214 Exhibited a Greater Than 5-Fold Boost in Neutralizing Antibodies Against BA.4 and BA.5 Subvariants in Phase 2/3 Study
Data Being Submitted to Regulators and for Peer Reviewed Publication
CAMBRIDGE, MA / ACCESSWIRE / June 22, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent (Omicron) COVID booster candidate, mRNA-1273.214. One month after administration in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited potent neutralizing antibody responses against the Omicron subvariants BA.4 and BA.5 in all participants regardless of prior infection. Based on this and prior data, the Company is working to complete regulatory submissions in the coming weeks requesting to update the composition of the booster vaccine to mRNA-1273.214.
In today's data, mRNA-1273.214 boosted neutralizing titers against BA.4/BA.5 by 5.4-fold (95% CI: 5.0, 5.9) above baseline in all participants regardless of prior infection, and by 6.3-fold (95% CI: 5.7, 6.9) in the subset of seronegative participants. Neutralizing titers against BA.4/BA.5 were approximately 3-fold lower than previously reported neutralizing titers against BA.1. One month after an mRNA-1273.214 booster, neutralizing geometric mean titers (GMT) against BA.4/BA.5 were 941 (95% CI: 826, 1071) in all participants, and 727 (95% CI: 633, 836) in seronegative participants. For context, prior studies of a third dose of the prototype booster induced neutralizing GMT against BA.1 of 629 (95% CI: 526, 751) and against Delta of 828 (95% CI: 738, 928)[1]. A third dose of the prototype booster was shown to be effective against Delta and BA.1 infection and hospitalization in observational studies [2],[3].
"In the face of SARS-CoV-2's continued evolution, we are very encouraged that mRNA-1273.214, our lead booster candidate for the fall, has shown high neutralizing titers against the BA.4 and BA.5 subvariants, which represent an emergent threat to global public health," said Stéphane Bancel, Chief Executive Officer of Moderna. "We will submit these data to regulators urgently and are preparing to supply our next generation bivalent booster starting in August, ahead of a potential rise in SARS-CoV-2 infections due to Omicron subvariants in the early fall."
Today's data add to results shared earlier this month from the Company's ongoing Phase 2/3 study in approximately 800 participants. Previous results showed a 50 µg booster dose of mRNA-1273.214 met all pre-specified primary endpoints, including superiority in neutralizing antibody GMT against Omicron (BA.1) when compared to a 50 µg booster dose of the prototype booster (mRNA-1273). The bivalent booster was generally well tolerated, with a reactogenicity and safety profile that was consistent with the prototype booster. Moderna believes these data collectively support updating the composition of the Company's booster to bivalent (Omicron) mRNA-1273.214 for the fall.
The Company has already shared these data with regulators and is submitting a manuscript for peer reviewed publication.
About Moderna
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: the Company's development of a bivalent booster vaccine targeted at the Omicron variant of the SARS-CoV-2 virus (mRNA-1273.214); the ability of mRNA-1273.214 to trigger an antibody response against the Omicron subvariants BA.4 and BA.5; the Company's submission of data to regulators in support of authorization of mRNA-1273.214 as a fall booster; and the safety and tolerability profile of mRNA-1273.214. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date hereof.
Moderna Contacts
Media:
Chris Ridley
617-800-3651
Vice President, Corporate Communications & Head of Media
Chris.Ridley@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View source version on accesswire.com:
https://www.accesswire.com/706099/Moderna-Announces-Bivalent-Booster-mRNA-1273214-Demonstrates-Potent-Neutralizing-Antibody-Response-Against-Omicron-Subvariants-BA4-And-BA5
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Kraft Heinz, Braskem, and Tenaris to headline OMP Conference São Paulo 202617.2.2026 15:00:00 CET | Press release
Global industry leaders showcase real-world results and AI-driven supply chain planning innovations SÃO PAULO, BR / ACCESS Newswire / February 17, 2026 / OMP, a leading provider of AI-powered supply chain planning solutions, brings its REAL conference series to Latin America with a one-day event in São Paulo on April 16, 2026. The conference will bring together Fortune 500 leaders to share how they are transforming global operations through digital innovation. Under the theme "Real expertise. Real solutions. Real results," the conference focuses on the practical application of AI in complex supply chain environments. The agenda is anchored by three global powerhouses who will provide a "behind-the-scenes" look at their digital transformation journeys in partnership with OMP's Unison Planning™: Kraft Heinz, a global food and beverage company, will demonstrate how data-driven planning, AI-enabled optimization, and end-to-end visibility are building a more agile and sustainable value chai
Supported by U.S. Polo Assn., the 2026 U.S. Open Women's Polo Championship(R) Concludes with Victory Eastern Hay the Champion17.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL / ACCESS Newswire / February 17, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the 2026 U.S. Open Women's Polo Championship®, which concluded on February 15 at the USPA National Polo Center (NPC) in Wellington, Florida, on the iconic U.S. Polo Assn. Stadium Field. Widely regarded as the most prestigious women's polo tournament in the United States, the championship brought together the sport's top athletes for three weeks of elite competition at the heart of American polo.1. Victory Eastern Hay proudly displaying their trophy as winner of the 2026 U.S. Open Women's Polo Championship at the USPA National Polo Center 2. Victory Eastern Hay Team on horseback (#1 Rebecca Schmeits, #2 Aspen Tinto, #3 Hazel Jackson, #4 Milly Hine) at the 2026 U.S. Open Women's Polo Championship 3. La Dolfina Team presents a donation to their charity of choice, Polo Players Support Group, provided by U.S. Polo Assn., at th
Camino Intercepts High-Grade Copper with 83.5m at 0.94% Cu including 7.1m at 2.13% Cu at Los Chapitos, Peru17.2.2026 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company")is pleased to announce the exploration results from Phase 1 of the recent drilling campaign at its Los Chapitos copper project ("Los Chapitos" or the "Project") in Peru. This news release reports the results from eight drill holes completed along the Diva trend corridor, where drilling activities focused on several targets with the objective of expanding the known mineralized body and improving the understanding of the scale and continuity of the mineralized system. Los Chapitos is Camino's second copper project with partner Nittetsu Mining Co, Ltd. ("Nittetsu"), who is completing a 35% earn-in interest in Los Chapitos after investing CAD $10 million and after the completion of Phase 2 of the current drilling campaign (see news release dated June 14, 2023). Camino is also advancing its Puquios Copper Project in Chile with Nittetsu Mining towards mine cons
Datavault AI Updates Revenue Estimates by Approximately 30% at $38M to $40M17.2.2026 12:00:00 CET | Press release
PHILADELPHIA, PA / ACCESS Newswire / February 17, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today announced its updated preliminary (unaudited) fiscal year 2025 revenue is estimated to be $38 to $40 million, exceeding its prior estimate of $30 million by up to 33%. At its midpoint, estimated FY-25 revenue represents approximately 1,300% growth year-over-year The Company attributed this revenue growth to its customer tech-licensing fees, and its Data Science Group's tokenization and monetization services. Further, Datavault AI reaffirmed its anticipated FY-26 revenue of $200 million, which, if achieved, would represent a year-over-year increase of 400% to 440%. KEY FINANCIAL METRICS FY 2025 (Preliminary, Unaudited): Estimated Revenue: $38-$40 million Prior Estimate: $30 million Incremental Change: +$8-$10 million (+27% to +33%) Midpoint:
Skymantics Europe Leverages DataGenesis to Power Next-Gen European Digital Twins with High-Fidelity Synthetic Populations16.2.2026 11:00:00 CET | Press release
ZARAGOZA, ES / ACCESS Newswire / February 16, 2026 / Skymantics Europe's DataGenesis platform supports the evolution of European Digital Twins. By providing high-accuracy, high-resolution synthetic population datasets, DataGenesis enables the simulation of complex demographic, socioeconomic, and health attributes, allowing for precise future scenario planning and more resilient policy-making across the continent. As Europe moves into a more sophisticated phase of digital modeling, the need to integrate the "human dimension" into Earth-system and urban models is paramount. DataGenesis addresses this by generating "digital twins" of populations that maintain the statistical integrity and multidimensional complexity of real-world communities-without utilizing or exposing sensitive personal information. Integrating Human Dynamics into Digital Ecosystems Skymantics' DataGenesis platform bridges the gap between environmental data and societal impact. Its mature model-based AI approach provid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom